<DOC>
	<DOC>NCT00946673</DOC>
	<brief_summary>The purpose of this study is to determine the maximum tolerated dose (MTD) of vorinostat given concurrently with stereotactic radiosurgery (SRS) to treat non-small cell lung cancer (NSCLCA) brain metastases in patient with 1-4 lesions.</brief_summary>
	<brief_title>Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>All patients age 18 years and older with histologically proven nonsmall cell lung cancer and 14 brain metastases, each measuring less than 2 cm will be eligible. Prior surgery or radiation is allowed as long as the target metastatic lesion(s) has not been treated with previous radiation. Adequate organ function (section 3.1.10). ECOG performance status 02. Life expectancy of &gt;=12 weeks. Systemic chemotherapy washout period &gt;=7 days. Patients who have previously been treated with whole brain irradiation, pediatric patients (age &lt;18), pregnant women, and patients who are unable to give informed consent.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>